Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Eli Lilly has suffered through the biggest setbacks in late-stage drug development work for Alzheimer’s — piling up high-profile failures for semagacestat, solanezumab and just …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.